Paper20160026
Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.
Pang X and 7 others. Cancer Res, 2010. Cited by 193 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Papers, record 20160026. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20160026
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Intracellular Signaling Peptides and Proteins | Major topic |
| Prostatic Neoplasms | Major topic |
| Protein Serine-Threonine Kinases | Major topic |
| Proto-Oncogene Proteins c-akt | Major topic |
| Triterpenes | Major topic |
| Animals | |
| Apoptosis | |
| Cell Growth Processes | |
| Cell Line, Tumor | |
| Chemotaxis | |
| Endothelial Cells | |
| Humans | |
| Male | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Neovascularization, Pathologic | |
| Pentacyclic Triterpenes | |
| Ribosomal Protein S6 Kinases, 70-kDa | |
| Specific Pathogen-Free Organisms | |
| TOR Serine-Threonine Kinases | |
| Vascular Endothelial Growth Factor A | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-124787-01A2 | NCI NIH HHS | United States | PubMed | PubMed | |
| CA-16672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| P01 CA124787 | NCI NIH HHS | United States | P01CA124787 | PubMed and NIH | NIH RePORTER |
| R01 CA106479 | NCI NIH HHS | United States | R01CA106479 | PubMed and NIH | NIH RePORTER |
| 1R01CA106479 | NCI NIH HHS | United States | R01CA106479 | PubMed and NIH | NIH RePORTER |
| P30CA016672 | NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 30709873 | Correction: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway. | https://conductscience.org/library/papers/30709873 |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11669150 | A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. | J Rheumatol | 2001 | https://conductscience.org/library/papers/11669150 | PubMed |
| 2 | 17110449 | Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. | Blood | 2007 | https://conductscience.org/library/papers/17110449 | PubMed |
| 3 | 18829578 | Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. | Cancer Res | 2008 | https://conductscience.org/library/papers/18829578 | PubMed |
| 4 | 15840409 | Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. | Eur J Pharmacol | 2005 | https://conductscience.org/library/papers/15840409 | PubMed |
| 5 | 19075588 | mTOR pathway and mTOR inhibitors as agents for cancer therapy. | Curr Cancer Drug Targets | 2008 | https://conductscience.org/library/papers/19075588 | PubMed |
| 6 | 16322239 | Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. | Cancer Res | 2005 | https://conductscience.org/library/papers/16322239 | PubMed |
| 7 | 16169463 | The Akt-mTOR tango and its relevance to cancer. | Cancer Cell | 2005 | https://conductscience.org/library/papers/16169463 | PubMed |
| 8 | 19567671 | Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. | Cancer Res | 2009 | https://conductscience.org/library/papers/19567671 | PubMed |
| 9 | 11513350 | Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. | Prog Neuropsychopharmacol Biol Psychiatry | 2001 | https://conductscience.org/library/papers/11513350 | PubMed |
| 10 | 19047305 | Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19047305 | PubMed |
| 11 | 18653228 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. | Lancet | 2008 | https://conductscience.org/library/papers/18653228 | PubMed |
| 12 | 15149849 | Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. | Exp Cell Res | 2004 | https://conductscience.org/library/papers/15149849 | PubMed |
| 13 | 17693255 | IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. | Cell | 2007 | https://conductscience.org/library/papers/17693255 | PubMed |
| 14 | 16909005 | Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. | Neurodegener Dis | 2005 | https://conductscience.org/library/papers/16909005 | PubMed |
| 15 | 18339865 | Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. | Cancer Res | 2008 | https://conductscience.org/library/papers/18339865 | PubMed |
| 16 | 16984800 | Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. | Biochem Pharmacol | 2006 | https://conductscience.org/library/papers/16984800 | PubMed |
| 17 | 16651429 | Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. | Cancer Res | 2006 | https://conductscience.org/library/papers/16651429 | PubMed |
| 18 | 18177721 | The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. | Cell Metab | 2008 | https://conductscience.org/library/papers/18177721 | PubMed |
| 19 | 17803898 | Molecular understanding and modern application of traditional medicines: triumphs and trials. | Cell | 2007 | https://conductscience.org/library/papers/17803898 | PubMed |
| 20 | 16769766 | Tripterine inhibits the expression of adhesion molecules in activated endothelial cells. | J Leukoc Biol | 2006 | https://conductscience.org/library/papers/16769766 | PubMed |
Cited by101
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 193 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943713 | Celastrol and Its Derivatives in Breast, Ovarian, and Cervical Cancer: Molecular Targets, Signalling Networks, and Nanocarrier-Based Delivery. | Molecules | 2026 | https://conductscience.org/library/papers/42943713 | PubMed |
| 42366741 | Celastrol Suppresses Porcine Deltacoronavirus Replication by Modulating Endoplasmic Reticulum Stress-Associated Ca2+ Balance. | Transbound Emerg Dis | 2026 | https://conductscience.org/library/papers/42366741 | PubMed |
| 41257273 | Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed? | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/41257273 | PubMed |
| 40480957 | Unveiling the Potential Binding Targets of Celastrol in Colorectal Cancer: A Proteomic Profiling Approach Integrating Cellular Thermal Shift Assay and Pulse Proteolysis. | J Proteome Res | 2025 | https://conductscience.org/library/papers/40480957 | PubMed |
| 39877708 | Advances in gastrointestinal vascular bleeding disorders: Successful sirolimus treatment in colonic angioectasia. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/39877708 | PubMed |
| 39494324 | Recent Trends in anti-tumor mechanisms and molecular targets of celastrol. | Int J Biol Sci | 2024 | https://conductscience.org/library/papers/39494324 | PubMed |
| 39456849 | Transcriptome and Metabolome Reveal Accumulation of Key Metabolites with Medicinal Properties of Phylloporia pulla. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39456849 | PubMed |
| 38881873 | Celastrol alleviates diabetic vascular injury via Keap1/Nrf2-mediated anti-inflammation. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38881873 | PubMed |
| 38203539 | Withaferin A and Celastrol Overwhelm Proteostasis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203539 | PubMed |
| 37110167 | Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics. | Metabolites | 2023 | https://conductscience.org/library/papers/37110167 | PubMed |
| 36967728 | The genome of Tripterygium wilfordii and characterization of the celastrol biosynthesis pathway. | GigaByte | 2021 | https://conductscience.org/library/papers/36967728 | PubMed |
| 36678677 | Targeting OPA1-Mediated Mitochondrial Fusion Contributed to Celastrol's Anti-Tumor Angiogenesis Effect. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36678677 | PubMed |
| 36567856 | Brevilin A Inhibits VEGF-Induced Angiogenesis through ROS-Dependent Mitochondrial Dysfunction. | Oxid Med Cell Longev | 2022 | https://conductscience.org/library/papers/36567856 | PubMed |
| 36367667 | Targeting PI3K/Akt signaling in prostate cancer therapy. | J Cell Commun Signal | 2023 | https://conductscience.org/library/papers/36367667 | PubMed |
| 36120370 | SHP2 inhibition improves celastrol-induced growth suppression of colorectal cancer. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36120370 | PubMed |
| 36017049 | Celastrol inhibits laser-induced choroidal neovascularization by decreasing VEGF induced proliferation and migration. | Int J Ophthalmol | 2022 | https://conductscience.org/library/papers/36017049 | PubMed |
| 35782744 | Celastrol inhibits the proliferation and migration of MCF-7 cells through the leptin-triggered PI3K/AKT pathway. | Comput Struct Biotechnol J | 2022 | https://conductscience.org/library/papers/35782744 | PubMed |
| 35695424 | Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway. | Cell Cycle | 2022 | https://conductscience.org/library/papers/35695424 | PubMed |
| 35359864 | Celastrol Alleviates Autoimmune Hepatitis Through the PI3K/AKT Signaling Pathway Based on Network Pharmacology and Experiments. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35359864 | PubMed |
| 35273658 | Functional metabolome profiling may improve individual outcomes in colorectal cancer management implementing concepts of predictive, preventive, and personalized medical approach. | EPMA J | 2022 | https://conductscience.org/library/papers/35273658 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20160026
GET https://conductscience.org/api/papers/v1/20160026/references?page=2